Evidence map›Paper›PMID 33569501›Full record

ArticleERJ open research2021

Validation of a diagnosis-agnostic symptom questionnaire for asthma and/or COPD.

Niklas Karlsson, Mark J Atkinson, Hana Müllerová, Marianna Alacqua, Christina Keen, Rod Hughes, Christer Janson, Barry Make, David Price, Helen K Reddel and 1 more

Registry-linked trialAbstract read
In one paragraph

Article in ERJ open research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02760329 (A NOVEL Observational longiTudinal studY on Patients With Asthma and/or COPD to Describe Patient Characteristics, Treatment Patterns and the Burden of Illness Over Time and to Identify Phenotypes and Endotypes.), which is not on this map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02760329 completednot on this map

A NOVEL Observational longiTudinal studY on Patients With Asthma and/or COPD to Describe Patient Characteristics, Treatment Patterns and the Burden of Illness Over Time and to Identify Phenotypes and Endotypes.

TypeobservationalSponsorAstraZenecaRan2016 to 2023Enrolled12,255ConditionsAsthma, COPD, Chronic Obstructive Pulmonary DiseaseArmsBlood draw, Urine, Lung function measurements, Fractional Exhaled Nitric Oxide (FENO)
3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Quality of life in patients with chronic respiratory failure on home mechanical ventilation.European respiratory review : an official journal of the European Respiratory Society · 2023
    Review
  7. Observational
  8. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Niklas KarlssonBioPharmaceuticals Medical, AstraZeneca, Gothenburg, Sweden.
Mark J AtkinsonEvidera, Bethesda, MD, USA.
Hana MüllerováBioPharmaceuticals Medical, AstraZeneca, Cambridge, UK.
Marianna AlacquaBioPharmaceuticals Medical, AstraZeneca, Cambridge, UK.
Christina KeenBioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Rod HughesBioPharmaceuticals Medical, AstraZeneca, Cambridge, UK.
Christer JansonDept of Medical Sciences: Respiratory, Allergy and Sleep Research, Uppsala University, Uppsala, Sweden.ORCID https://orcid.org/0000-0001-5093-6980
Barry MakeNational Jewish Health and University of Colorado Denver, Denver, CO, USA.ORCID https://orcid.org/0000-0003-4349-8745
David PriceObservational and Pragmatic Research Institute, Singapore, Singapore.ORCID https://orcid.org/0000-0002-9728-9992
Helen K ReddelWoolcock Institute of Medical Research, University of Sydney, Sydney, Australia.ORCID https://orcid.org/0000-0002-6695-6350
NOVELTY study investigators

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The Respiratory Symptoms Questionnaire (RSQ) is a novel, four-item patient-reported diagnosis-agnostic tool designed to assess the frequency of respiratory symptoms and their impact on activity, without specifying a particular diagnosis. Our objective was to examine its validity in patients with asthma and/or chronic obstructive pulmonary disease (COPD). Methods: Baseline data were randomly sampled from patients who completed the RSQ in the NOVELTY study (ClinicalTrials.gov: NCT02760329). The total sample (n=1530) comprised three randomly selected samples (n=510 each) from each physician-assigned diagnostic group (asthma, asthma+COPD and COPD). The internal consistency and structural validity of the RSQ were evaluated using exploratory and confirmatory factor analyses; psychometric performance was observed using Classical Test Theory and Item Response Theory analyses. Results: For the total sample, the mean±sd RSQ score was 5.6±4.3 (range 0-16). Irrespective of diagnosis, the internal consistency of items was uniformly adequate (Cronbach's α=0.76-0.80). All items had high factor loadings and structural characteristics of the measure were invariant across groups. Using the total sample, RSQ items informatively covered the θ score range of -2.0 to 2.8, with discrimination coefficients for individual items being high to very high (1.7-2.6). Strong convergent correlations were observed between the RSQ and the St George's Respiratory Questionnaire (0.77, p<0.001). Conclusions: The RSQ is a valid, brief, patient-reported tool for assessing respiratory symptoms in patients across the whole spectrum of asthma and/or COPD, rather than using different questionnaires for each diagnosis. It can be used for monitoring respiratory symptoms in clinical practice, clinical trials and real-world studies.

Identifiers

PMID33569501
PMCPMC7861031

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.